https://orcid.org/0000-0002-4542-4232
Overview
Medical Director, Cellular Therapy Program
Hematologic oncologist specializing in the care of patients with acute leukemias and aggressive lymphomas, and those patients who require administration of an immune effector cellular therapy. Dr. Lin oversees Duke's cellular therapy program, which provides cell-based treatments such as chimeric antigen receptor T (CAR T) cell therapy, engineered T cell receptor (TCR) therapy, and tumor infiltrating lymphocytes (TILs) for a variety of cancers and autoimmune disorders. His research interests include clinical trials, digital health, and real-world evidence.
Fellowship: Duke Cancer Institute
Residency: Northwestern University
Medical School: University of Chicago Pritzker School of Medicine
Undergraduate: Yale University
Hematologic oncologist specializing in the care of patients with acute leukemias and aggressive lymphomas, and those patients who require administration of an immune effector cellular therapy. Dr. Lin oversees Duke's cellular therapy program, which provides cell-based treatments such as chimeric antigen receptor T (CAR T) cell therapy, engineered T cell receptor (TCR) therapy, and tumor infiltrating lymphocytes (TILs) for a variety of cancers and autoimmune disorders. His research interests include clinical trials, digital health, and real-world evidence.
Fellowship: Duke Cancer Institute
Residency: Northwestern University
Medical School: University of Chicago Pritzker School of Medicine
Undergraduate: Yale University
Current Duke Appointments & Affiliations
Assistant Professor of Medicine
·
2023 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Member of the Duke Cancer Institute
·
2023 - Present
Duke Cancer Institute,
Institutes and Centers
Recent News Items
View All News Items
Recent Scholarly Works
Hybrid-delivered cognitive behavioral symptom management and activity coaching intervention for patients following hematopoietic stem cell transplant or CAR T-cell therapy: Protocol of a randomized controlled trial.
Journal article Contemp Clin Trials · July 2026 BACKGROUND: Patients undergoing hematopoietic stem cell transplant (HCT) and chimeric antigen receptor T-cell (CAR-T) therapy experience significant disability exacerbated by persistent fatigue, pain, and psychological distress. These symptoms limit physic ... Full text Link to item CiteAllogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel (Brexu-cel) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA).
Journal article Transplant Cell Ther · June 27, 2026 INTRODUCTION: Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor T (CAR T) cell therapy approved for adults with relapsed/refractory (r/r) B-ALL. Despite encouraging outcomes, the majority of adults relapse following ... Full text Link to item CiteImproved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL.
Journal article Blood Adv · June 25, 2026 Brexucabtagene-autoleucel (brexu-cel) produces high rates of measurable residual disease-negative (MRD-) complete response (CR) in adults with Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL); however, subsequent relapses remain fr ... Full text Link to item CiteRecent Grants
Lyell Immunopharma, Inc. / A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel, an Autologous, Dual-Targeting CD19/CD20 CAR T-Cell Therapy Product Candidate, Versus Investigator?s Choice of CD19 CAR T-Cell Therapy in Patients with Rela
Clinical TrialPrincipal Investigator · Awarded by Lyell Immunopharma, Inc. · 2026 - 2031Pathological B Cells: Novel Strategies to Prevent and Treat Chronic GVHD
ResearchCo Investigator · Awarded by National Institutes of Health · 2015 - 2031Randomized Controlled Trial of a Hybrid-Delivered Cognitive Behavioral Symptom Management and Activity Coaching Intervention for Stem Cell Transplant Patients
ResearchCo Investigator · Awarded by National Institutes of Health · 2024 - 2029View All Grants
Education
The University of Chicago ·
2016
M.D.